Clinical Trial Update: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C [Phase 3]

View source ↗

Summary

Phase III trial evaluating BMS-790052 (daclatasvir) added to pegylated interferon alfa-2a and ribavirin in treatment-naive hepatitis C patients; the trial is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-790052 (daclatasvir) (daclatasvir)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 3 | Status: COMPLETED | Results posted: 2015-09-07